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The blood coagulation system of 66 consecutive patients 
undergoing consecutive liver transplantations was moni-
tored by thrombelastograph and analytic coagulation profile. 
A poor preoperative coagulation state, decrease in levels of 
coagulation factors, progressive fibrinolysis, and whole blood 
clot lysis were observed during the preanhepatic and an-
hepatic stages of surgery. A further general decrease in 
coagulation factors and platelets, activation of fibrinolysis, 
Liver transplantation, which began as highly exper-
imental surgery 20 yr ago, is now recognized as a 
major means of therapy for patients with end-stage 
liver disease (1). However, massive blood loss during 
liver transplantation is still a major concern. The liver 
produces most of the blood coagulation factors, so it 
is not surprising that we see very low levels of these 
factors and prolonged prothrombin time (PT) and ac-
tivated partial thromboplastin time (aP1T) in many 
patients receiving liver transplants (2). Frequently we 
have seen thrombocytopenia, which may result from 
gastrointestinal bleeding, splenomegaly, or malnu-
trition (3). At the same time, numerous collateral 
channels and portal hypertension, together with in-
creased capillary fragility, make maintenance of sur-
gical hemostasis very difficult. 
Previous studies on the blood coagulation system 
in humans and in animals; undergoing liver trans-
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and abrupt decrease in levels of factors Vand VIII occurred 
before and with reperfusion of the homograft. Recovery of 
blood coagulability began 30-60 min after reperfusion of 
the graft liver, and coagulability had returned toward base-
line values 2 hr after reperfusion. A positive correlation was 
shown between the variables of thrombelastography and those 
of the coagulation profile. Thrombelastography was shown 
to be a reliable and rapid monitoring system. Its use was 
associated with a 33% reduction of blood and fluid infusion 
volume, whereas blood coagulability was maintained with-
out an increase in the number of blood product donors. 
Key Words: BLOOD-coagulation. LIVER-trans-
plantation. 
plantation have demonstrated dilutional coagulop-
athy associated with massive blood transfusion, de-
creased fibrinogen levels, and thrombocytopenia (4,5). 
Fibrinolysis, beginning during the anhepatic stage of 
surgery and becoming "explosive" on reperfusion of 
the homograft, has been reported (6). A consumption 
coagulopathy accompanied by an increased level of 
fibrin degradation products appeared to playa major 
role (7). However, these observations were limited to 
a few patients in the early era of liver transplantation, 
and comprehensive information is still lacking. 
Another difficulty in the intraoperative manage-
ment of liver transplantation has been actively mon-
itoring the coagulation system and determining the 
appropriate treatment during dynamic blood volume 
changes. The use of the thrombelastograph (rEG) was 
suggested by von Kaulla et al. (4) and Howland et al. 
(8). However, the efficacy of thrombelastographic 
monitoring of blood coagulation during liver trans-
plantation has not been established. 
The purpose of our study was to investigate the 
changes in the blood coagulation system, the clinical 
applicability of thrombelastography as a monitoring 
system, and the clinical effectiveness of thrombelas-
tography-guided replacement therapy in a large group 
of patients undergoing liver transplantation. 
COAGULATION IN LIVER TRANSPLANTATION 
IV IV 
Blood filter 
To#IOg 
.->C.""-'-.>:----1 ~~ ~~: or 
ANESTH ANALG 
1985;64:888-96 
889 
Figure 1. A rapid infusion system, de-
veloped by JJ Sassano, MD, of the Univer-
sity of Pittsburgh School of Medicine. 
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Methods 
Patients undergoing liver transplantation between 
February 1983 and January 1984 were observed as 
prospective members for the study. All patients had 
two indwelling 8.5-French catheters inserted for vol-
ume infusion, one in an antecubital vein and another 
in an internal or an external jugular vein. In addition, 
a flow-directed pulmonary arterial catheter was in-
serted via the right internal jugular vein, and an in-
dwelling catheter was placed in a radial artery. Nor-
mal saline solution without heparin was used for 
continuous flushing of the pressure-monitoring cath-
eters to avoid anticoagulant effects. A rapid infusion 
system was developed (by JJ Sassano, University of 
Pittsburgh School of Medicine), which was able to 
deliver warmed, premixed fluid at a rate of up to 2000 
ml/min (Fig. 1). This device was used to replace lost 
blood volume with a fluid composed of red blood cells 
(RBC), fresh frozen plasma (FFP), and electrolyte so-
lution (Plasma-Iyte A, Travenol Laboratories Inc., 
Deerfield, IL 60015) in a ratio of 300: 200: 250 m!. All 
blood products were preserved with citrate phosphate 
and dextrose with adenine (CPDA-1). Intraoperative 
volume infusion was guided by systolic blood pres-
sure, heart rate, and pulmonary capillary occlusion 
pressure measurements. Arterial blood gas tensions 
and serum electrolytes, glucose, and ionized calcium 
levels were monitored every hour, though more fre-
quently if clinically indicated. 
Coagulation tests employed previously described 
methods (9-11) and were performed for patient care 
purposes at times when sudden or profound changes 
were anticipated. Blood samples (15 ml each) were 
eXfensions 
obtained at various intervals: before induction of 
anesthesia; 30 min after beginning the operation; 
thereafter every 2 hr or after infusion of every 6 L of 
blood volume; 5 min into the anhepatic stage; 30 min 
into the anhepatic stage; 5 min after reperfusion of 
the homograft; 30 min after reperfusion; and there-
after every 2 hr or after infusion of every 6 L of blood 
volume. The blood coagulation profile included mea-
surements of PT; aPTT; thrombin time (TT); reptilase 
time; levels of factors I, II, V, VII, VIII, IX, X, XI, and 
XII; fibrin degradation product (FDP) level; euglobulin 
lysis time (ELT); and platelet count. 
At the same time, whole blood was used for throm-
belastographic monitoring of blood coagulation (12). 
Whole blood (0.36 ml) was placed in the Thrombe-
lastograph D (Hellige Company, Freiburg, Germany), 
and four drops of mineral oil were spread over the 
blood surface to prevent evaporation of blood. The 
recording began 4 min from the blood sampling time. 
The TEG is shown schematically in Figure 2. It re-
peatedly measures the shear elasticity of a blood clot 
from the time when the first fibrin strands are formed 
to the completion of the clot formation, including fi-
brinolysis. An oscillating cup contains 0.36 rnl of whole 
blood kept at 37°C. A pin, suspended by a torsion 
wire, is lowered into the blood specimen in the cup. 
While the blood remains fluid, the container motion 
does not influence the pin. Once the clot begins to 
form, the fibrin strands gradually strengthen their 
hold on the cup and pin. Therefore, the cup is coupled 
to the pin; and the shear elasticity of the blood clot, 
which is transmitted to the pin, is recorded on thermal 
paper. The TEG records the activity of whole blood 
coagulation (13), including cellular and humoral ele-
890 ANESTH ANALG 
1985;64:888-96 
Torsion wire 
Pin 
> 
Cup 
(Whole blood, 
.36 ml) 
Fibrin strand TEG recording 
Figure 2. Thrombelastography: sensitive bedside monitoring of co-
agulation. It measures the shear elasticity of a blood clot from the 
time when the first fibrin strands are formed to the completion of 
the clot formation, including fibrinolysis. 
ments such as interactions of RBC, platelets, coagu-
lation factors, and calcium. The following variables 
were measured (Fig. 3): reaction time (R, min); max-
imum amplitude (MA, mm); amplitude 60 min after 
MA (A60, mm); coagulation time (R + k, min); clot 
formation rate (a, 0); blood clot lysis time (F, min); 
and blood clot lysis index (Aro'MA x 100, %). 
The blood product replacement therapy was guided 
by the results of thrombelastographic monitoring. A 
prolonged reaction time (R > 15 min) was treated with 
2 units of FFP and a decrease in maximum amplitude 
(MA < 40 mm), with 10 units of platelets. Cryopre-
cipitate (6 units) was infused when the above therapy 
did not improve coagulation or when the clot for-
mation rate was slow (a < 45°). However, because 
the anhepatic stage of surgery included veno-venous 
bypass (femoral and portal vein to axillary vein) with-
out systemic heparinization, 'infusion of platelets and 
cyroprecipitate was withheld during that stage to lessen 
the chance of thromboembolism. To evaluate the clin-
ical effectiveness of qbd-gui~ed replacement therapy, 
the blood volume infused in these patients (TEG-
monitored group) was compared with that of a group 
of patients who received liver transplants between 
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August 1981 and January 1983 without TEG moni-
toring (nonmonitored group). 
The measurements of all the coagulation factor lev-
els, thrombelastographic variables, and infused blood 
product volumes were analyzed by analysis of vari-
ance of repeated measures, nonparametric Wilcoxon 
test, linear regression, and K-analysis. P < 0.05 was 
considered statistically significant. 
Results 
Sixty-six adult patients received liver transplants be-
tween February 1983 and January 1984. Three patients 
for whom data were insufficient were excluded from 
the analysis. The surgical procedure was arbitrarily 
divided into three distinct stages: stage I, isolation of 
the host liver; stage II, the anhepatic stage; and stage 
III, postreperfusion of the graft liver. 
Changes in Coagulation Profile 
Patients were divided into six groups according to the 
etiology of their underlying disease: primary biliary 
cirrhosis, postnecrotic cirrhosis, sclerosing cholangi-
tis, neoplasm, miscellaneous liver diseases, and re-
transplantation. Preoperative diagnoses in the mis-
cellaneous group were cryptogenic cirrhosis, acute 
chemical hepatitis, Wilson's disease, hemochroma-
tosis, and aI-antitrypsin deficiency. Preoperative co-
agulation profiles were abnormal in a large proportion 
of patients: PT in 41 (65%), aPTT in 45 (71 %), factor 
I level in 9 (14%), factor V level in 37 (59%), factor VII 
level in 35 (56%), factor VIII level in 2 (3%), and plate-
let count in 44 (70%). ELT was less than 2 hr in 17 
patients (27%), and FOP was positive in 15 patients 
(24%). The mean preoperative coagulation profile of 
each disease group is shown in Table 1. PT was pro-
longed in patients of all groups, and it was remarkably 
prolonged in patients in the postnecrotic cirrhosis and 
miscellaneous disease groups. aPTT was prolonged 
in all patients except those with neoplasms. The plate-
let count was significantly decreased in patients with 
sclerosing cholangitis and in the miscellaneous dis-
ease group. All patients except those in the miscel-
laneous group demonstrated a relatively normal fi-
brinogen level. The level of factor V was higher than 
0.5 Vlml in the patients of the neoplasm, primary 
biliary cirrhosis, and retransplantation groups. Factor 
VIII level was higher than 1.0 V/ml in all but six patients. 
Intraoperative coagulation profile and thrombelas-
tographic measurements of patients with primary bil-
iary cirrhosis (11 patients) are shown in Table 2. Dur-
ing stage I of surgery, PT and aPTT remained 
prolonged. All the coagulation factor levels, including 
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the platelet count, decreased progressively during 
surgery. In stage II (anhepatic stage) the levels of all 
coagulation factors did not change significantly, al-
though aPTT was progressively prolonged and EL T 
became shortened. On reperfusion of the homograft 
(stage III + 5 min), PT and aPTT were remarkably 
prolonged, and levels of all other coagulation factors 
were significantly decreased. With the progress of 
surgery, coagulation profiles improved slowly, begin-
ning 30 min after reperfusion (III + 30 min). At the 
end of surgery, PT and aPTT returned toward pre-
operative values, and platelet counts and the levels 
of coagulation factors, except factor V, returned 
toward clinically acceptable levels. The level of factor 
V, 0.23 ± 0.13 Vlml, was the lowest of the coagulation 
factors at the conclusion of surgery. Reptilase time 
and TT were measured in all 11 patients; both were 
moderately prolonged in all these patients, indicating 
a possible dysfibrinogenemia. A remarkably pro-
longed TT was noted in three patients: two at stage 
II and one at the beginning of stage III. A significant 
change was seen in ELT. The mean ELT, 215 ± 77 
min at the time of induction of anesthesia, decreased 
progressively during the first stage of surgery. It 
reached a minimum value at the time of reperfusion 
of the homograft (68 ± 53 min) and had returned 
toward the preoperative value at 2 hr in stage III (III 
+ 120 min). 
Intraoperative change in fibrinolytic activity in all 
patients is shown in Table 3. Four patients had an 
ELT of less than 1 hr at the beginning of surgery; that 
number increased to 21 by the time of homograft re-
perfusion. ELT improved toward preoperative values 
at the end of surgery, remaining shorter than 1 hr in 
only one patient. A significant number of patients (15) 
had a slightly positive test for FOP at the beginning 
of surgery. The number increased to 26 patients by 2 
hr after reperfusion of the homograft, and FOP re-
mained positive in 22 patients at the conclusion of 
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Figure 3. Variables and normal values 
measured by thrombelastography. Abbre-
viations: R-reaction time, 6-8 min; R + 
k-coagulation time, 10-12 min; a-clot 
formation rate, > 50°; MA-maximum 
amplitude, 50-70 mm; AbO-amplitude 60 
min after MA; A"oIMA·100-whole blood 
clot lysis index, > 85%; and F-whole 
blood clot lysis time, > 300 min. 
surgery, although the concentrations of FOP were never 
high. 
Thrombelastographic Variables 
The intraoperative change in TEG variables of patients 
with primary biliary cirrhosis is shown in Table 2. 
Preoperative values indicated a slightly prolonged re-
action time (R). The maximum amplitude (MA) and 
clot formation rate (a) were 54.6 ± 11.2 mm and 55.5 
± 8S, respectively. The whole blood clot lysis index 
EA~MA x 100) was 83%, which indicates whole blood 
clot lysis activity. The R value was prolonged during 
the early phase of the third stage of surgery. It was 
prolonged significantly at the time of reperfusion of 
the homograft (11.2 ± 5 min) and returned toward 
its preoperative value at 2 hr in stage III (8.8 ± 3.0 
min). The changes in R + k were similar to those in 
R. The whole blood clot lysis index decreased pro-
gressively from the beginning of surgery, and the 
lowest value was observed in the middle of the an-
hepatic stage. It improved after reperfusion of the 
homograft and returned toward the preoperative value 
at 2 hr in stage III. Intraoperative change of whole 
blood clot lysis activity in all patients is shown in Table 
3. Blood from three patients lysed within 2 hr at in-
duction of anesthesia; whole blood clot lysis was seen 
most frequently from the middle of stage II to 30 min 
into stage III. No patient's blood lysed within 2 hr at 
the conclusion of surgery. 
Correlation of Thrombelastographic Variables and 
Coagulation Profile 
To determine the correlation between the conven-
tional coagulation profile and the TEG variables, pre-
operative values were compared by linear regression 
analysis. In general, correlation between the variables 
of TEG and those of the coagulation profile was poor. 
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Table 1. Preoperative Coagulation Profile of Liver Transplantation Patients 
Primary biliary l'ostnecrotic Sclerosing Miscellaneous 
Variables Normal range Neoplasm cirrhosis cirrhosis cholangitis Disease Retransplant All patients 
Number of patients 9 13 11 6 9 15 63 
PT (sec) 10.8-13.0 13.3 ± 4.0 13.9 ± 1.7 15.7 ± 1.4 13.3 ± 3.6 18.9 ± 5.4 13.2 ± 1.5 14.8 ± 3.7 
aPTT (sec) 26-34 34.1 ± 6.3 41.0 ± 8.7 40.2 ± 4.1 42.4 ± 10.1 46.7 ± 10.6 41.7 ± 14.2 41.5 ± 13.9 
Platelets (1000/mm') 150-450 245 ± 151 181 ± 199 162 ± 178 86 ± 19 82 ± 64 116 + 115 147 + 144 
Fibrinogen (mg %) 150-450 323 ± 166 382 ± 116 247 ± 134 238 ± 44 167 ± 86 301 ± 149 292 ± 138 
Factor V (U/ml) 0.5-1.5 0.82 ± 0.41 0.54 ± 0.27 0.35 ± 0.12 0.47 ± 0.20 0.28 ± 0.23 0.66 ± 0.29 0.53 ± 0.32 
Factor VII (U/ml) 0.5-1.5 0.56 ± 0.25 0.83 ± 0.35 0.35 ± 0.25 0.71 ± 0.49 0.28 ± 0.24 0.53 ± 0.26 0.57 ± 0.39 
Factor VIII (U/ml) 0.5-1.5 1.42 ± 0.33 2.03 ± 0.73 1.82 ± 0.93 2.53 ± 1.30 2.30 ± 0.70 1.92 ± 1.35 2.00 ± 0.90 
ELT (min) >300 218 ± 48 215 ± 77 163 ± 87 218 ± 67 132 ± 68 247 ± 86 202 ± 81 
Sixty-three patients, values are mean ± so. 
Table 2. Intraoperative Changes in Coagulation of Patients with Primary Biliary Cirrhosis 
Stage I Stage II Stage III 
Before operation 120 min 5 min 30 min 5 min 30 min 120 min End 
PT (sec) 13.9 ± 1.7 13.7 ± 1.0 14.0 ± 1.3 13.8 ± 1.2 15.4 ± 1.6" 15.7 ± 1.5" 15.0 ± 1.4 14.6 ± 1.4 
aPTT (sec) 41.0 ± 8.7 40.2 ± 7.7 46.0 ± 12.9 51.2 ± 16.0 75.2 ± 39.2" 61.5 ± 23.6" 46.0 ± 9.7 38.4 ± 3.8 
Platelets (1000/mm3) 181 ± 199 150 ± 122 149 ± 120 154 ± 122 124 ± 63" 132 ± 61 134 ± 82 143 ± 74 
Fibrinogen (mg (;c) 323 ± 166 288 ± 100 252 ± 113 235 ± 88 194 ± 93" 195 ± 101" 191 ± 90" 210 ± 92 
Factor V (U/ml) 0.54 ± 0.27 0.43 ± 0.22 0.35 ± 0.19 0.38 ± 0.19 0.26 ± 0.18" 0.22 ± 0.13" 0.21 ± O.l1a 0.23 ± 0.13" 
Factor VII (U/ml) 0.83 ± 0.35 0.71 ± 0.37 0.62 ± 0.31 0.65 ± 0.27 0.52 ± 0.23a 0.52 ± 0.18" 0.53 ± 0.18 0.51 ± 0.17 
Factor VIII (U/ml) 2.03 ± 0.73 1.81 ± 0.86 1.51 ± 0.88 1.49 ± 0.75 1.11 ± 0.70" 0.82 ± 0.53a 0.87 ± O.44a 0.93 ± 0.35a 
ELT (min) 215 ± 77 134 ± 93 140 ± 88 101 ± 77a 68 ± 53" 108 ± 45 155 ± 63 185 ± 70 
R (min) 8.5 ± 2.4 8.2 ± 3.6 6.6 ± 3.4 7.5 ± 2.3 11.2 ± 5.0" 9.7 ± 2.7 8.8 ± 3.0 8.0 ± 2.9 
R + k (min) 12.0 ± 2.7 12.0 ± 6.3 9.5 ± 2.5 11.0 ± 2.2 23.5 ± 16.4" 15.0 ± 6.1 12.5 ± 4.5 10.0 ± 2.6 
it (0) 55.5 ± 8.5 53.8 ± 12.2 53.6 ± 10.4 53.1 ± 7.4 39.1 ± 17.5" 48.6 ± 10.5 50.6 ± 12.0 55.1 ± 8.0 
MA (mm) 54.6 ± 11.2 57.3 ± 9.4 52.3 ± 11.0 51.3 ± 9.4 38.2 ± 14.5" 51.7 ± 8.9 51.5 ± 11.9 52.1 ± 10.8 
A6u1MA·100 (%) 83.0 ± 7.8 76.4 ± 14.5 73.9 ± 27.0 65.5 ± 35.5 75.8 ± 34.4 79.8 ± 29.3 92.2 ± 8.6" 91.7 ± 6.7" 
Eleven patients; values are mean ± SD. "Significantly different from the corresponding preoperative value (P < 0.05). 
However, the reaction time correlated best with aPTT 
(r = 0.49, P < 0.001). MA correlated better with plate-
let count (r = 0.59, P < 0.001) and fibrinogen level 
(r = 0.64, P < 0.001). The whole blood clot lysis time 
(F) did correlate with ELT (r = 0.54, P < 0.05). There 
were 45 occasions when patients received platelets 
alone. The mean increase in platelet count was 40,200 
± 31,400/mm3 after infusion of 10 units of platelets; 
it correlated best with the MA value, which increased 
13.2 mm. When 6 units of cryoprecipitate were given 
alone, factor I increased by 37 mg% and factor VIII 
by 13 U/m!, while aPTT decreased by 5.7 sec. The 
corresponding changes in TEG variables were a de-
crease in reaction time by 1.2 min and an increase in 
clot formation rate by 9.4°. 
Comparison of Thrombelastograph-Monitored and 
Nonmonitored Groups 
The blood volume infused to patients in our series 
was compared with that required by a group of pa-
tients who received liver transplants between March 
1981 and January 1983, and who were not monitored 
by TEG. Five patients in the monitored group who 
received more than 100 units of RBC transfusion were 
excluded from the analysis. Seventeen patients in the 
nonmonitored group were excluded from the com-
parison-five patients who required more than 100 
units of RBC and 12 patients who underwent 
veno-venous bypass with systemic heparinization, 
some of whom developed uncontrollable bleeding. 
The preoperative diagnoses of patients in the two 
groups were not different (P > 0.5). The volume of 
blood given to patients in the two groups is shown 
in Table 4. Patients in the TEG-monitored group re-
ceived 17 ± 12.9 units of RI3C, whereas patients in 
the nonmonitored group required 26.7 ± 23.8 units 
of RBC (P < 0.05). A significant reduction in FFP 
infusion (18.3 ± 12.5 vs 26.7 ± 24.1 units) and a 
decrease in total fluids infused (20.2 ± 11.2 vs 
31.4 ± 19.2 L) were noted in patients of the TEG-
monitored group. On the other hand, significantly 
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Table 3. Intraoperative Changes in Number of Patients with Fibrinolytic Activity 
Stage I 
Befort, operation 30 min 120 min 
ELT 
'> 1 hr 48 41 25 
<1 hr 4 10 15 
FOP 
Negative 36 37 36 
Positive 15 16 16 
r 
>2 hr 55 53 51 
<2 hr 3 5 7 
more platelets (20.8 ± 12.8 vs 14.1 ± 13.7 units) and 
cryoprecipitate (17.2 ± 8.5 vs 10.2 ± 4.5 units) were 
infused to the TEG-monitored patients. The number 
of donors from whom each patient received blood was 
similar between the two groups (67.9 ± 43.9 vs 71.4 
± 63.4). 
Discussion 
As might be expected of patients with end-stage liver 
disease, preoperative coagulation profiles of many 
subjects studied showed prolonged PT and aPTT and 
decreased levels of factors produced by the liver. Co-
agulopathy was worse preoperatively in patients with 
miscellaneous types of liver disease and with post-
necrotic cirrhosis because these patients have more 
parenchymal hepatocellular damage, which disrupts 
the synthesis of the blood coagulation factors. Other 
patients, such as those with neoplasms, may have 
close to normal hepatic function. Supranormallevels 
of fibrinogen and factor VIII activity were observed 
in many of our patients. A similar high level of factor 
VIII was found previously (14) and may result from 
increased production related to a stress response, re-
lease from damaged liver cells, or impaired catabolism 
of factor VIII (15). Preoperative fibrinogen level was 
lower than normal in only 20% of the patients. How-
ever, moderate prolongation of both IT and reptilase 
time was common and suggests a possible dysfibrino-
genemia. Abnormal fibrin polymerization is known 
to occur in liver disease (16) and is reported to be 
related to an excessive sialic acid content in the fi-
brinogen molecule (17,18). The clinical significance of 
the acquired dysfibrinogenemia in patients with liver 
disease and its role in patients undergoing liver trans-
plantation requires further investigation. 
Throughout the surgical procedure, a fluid com-
posed of RBC, FFP, and Plasma-lyte A in a ratio of 
300: 200: 250 ml was used for volume replacement. 
RBC was mixed with FFP to supplement coagulation 
Stage II Stage III 
5 min 30 min 5 min 30 min 120 min End 
35 29 27 21 37 43 
14 20 21 13 
37 31 34 30 27 31 
17 21 20 22 26 22 
52 
6 
49 49 46 55 5S 
10 10 12 3 0 
factors. Plasma-Iyte A was added to decrease the loss 
of RBC and possibly to improve the circulatory rheol-
ogy. Plasma-Iyte A was chosen because it does not 
contain calcium, which can initiate clotting in the rapid 
infusion system; it does not contain glucose, which 
may cause hyperglycemia during massive blood 
transfusion; and it is isoosmolar. The blood mixture 
had levels of hematocrit, 27 ± 2; hemoglobin, 9 ± 
1.2 mg%; factor 1, 130 mg%; factor II, 0.59 U/ml; factor 
V, 0.21 U/ml; factor VII, 0.58 U/ml; and factor VIII, 
0.57 U/m!. Once blood volume was replaced by this 
mixture, platelets, fibrinogen, and factor VIII were 
replenished with transfusion of platelets or cryopre-
cipitate, guided by TEG monitoring. A coagulation 
factors-rich blood mixture was transfused, and the 
plasma levels of coagulation factors reached the levels 
in the transfused blood mixture rapidly as surgery 
progressed. The change is more likely due to a di-
lutional effect associated with surgical bleeding. As 
long as blood was simply entering the patient by 
transfusion and leaving by exsanguination, the di-
lutional effects should not bring the coagulation fac-
tors below those in the infused blood mixture. If fi-
brinolysis or intravascular coagulation occurred, 
differential falls in certain factors might be seen. 
No attempt was made to correct coagulopathy dur-
ing unheparinized veno-venous bypass in the an-
hepatic stage, in order to minimize possible throm-
bosis or embolization. Only RBC and FFP were infused 
to replace the blood volume. The increase in fibri-
nolytic activity was the most significant change in the 
coagulation pattern during the anhepatic stage. This 
relative lack of change in coagulation profile mea-
surements may be due to the relatively short duration 
of the second stage (89 ± 21 min; compared with 221 
± 80 min, stage 1; and 343 ± 123 min, stage III) 
or to the use of veno-venous bypass (19). It appears 
that the veno-venous bypass system, which used a 
heparin-coated Gott Aneurysm Shunt (Sherwood 
Medical, St. Louis, MO), did not interfere with the 
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Table 4. Comparison of Transfused Blood Volume 
between Thrombelastograph-Monitored Patients and 
Nonmonitored Patients 
nee-monitored Nonmonitored 
patients patients 
Bloud products (/I = 58) (/I = 47) 
Rl'd blood cells (unit) 17.0 ± 12.9" 26.7 ± 23.8 
Fresh frozen plasma (unit) 18.3 ± 12.5" 26.7 ± 24.1 
l'I"telets (unit) 20.8 ± 12.8" 14.1 ± 13.7 
Cryoprecipitate (unit) 12.2 ± 14.2" 3.9 ± 12.9 
Total blood products (unit) 67.9 ± 43.9 71.4 ± 63.4 
Crystalloid (litre) 10.2 ± 4.5" 17.2 ± 8.5 
Total volume infused (litre) 211.2 ± 11.2" 31.4 -+: 19.2 
V,dUL'S <1ft..' mean -+- c.,j), "Significantly differt'nt frum the corresponding 
\'<llul'" "f the nonmonitorcd patients (f' < D.DS). 
coagulation system, by thrombosis or by coagulopa-
thy, and may even have played a beneficial role, By 
decompressing the portal venous system and main-
taining venous return from the lower extremities, it 
could have decreased venous pressure to decrease 
bleeding and reduced the congestive ischemia of the 
viscera, which in turn might have minimized the met-
abolic acidosis that could have adversely affected the 
blood coagulation system. 
Reperfusion of the homograft was associated with 
significant coagulopathy, which was clearly demon-
strated by the TEG measurements: prolonged R, pro-
longed R + k, decreased MA, decreased a, and de-
creased F (which was shortened to 92 min, reflecting 
the decreased function of coagulation factors, includ-
ing fibrinogen and platelets, and active whole blood 
lysis). These findings, in agreement with reports by 
Groth (6) and by von Kaulla et al. (4), might have 
resulted from pathophysiologic changes that occur 
on reperfusion of the graft liver. First, there is an 
exaggerated dilutional effect. The influx of the organ 
preservation solution from the donor liver may con-
tribute further to the dilution of coagulation factors. 
Second, an active fibrinolytic process is evident in 
many patients. This could be due to release of tissue 
plasminogen activator from vascular endothelium (20) 
or to activation of protein C (21). Third, other inves-
tigators stressed disseminated intravascular coagu-
lation (OIC) as a major cause of the change (2,5), but 
there is little evidence of OIC in this study. Groth et 
a1. suggested that loss of hepatic clearance function 
played a role in fibrinolytic activation or that anti-
gen-antibody reaction might lead to DIC (2). How-
ever, the lack of high levels of circulating fibrin mono-
mers and FOP found in this study does not support 
a major role for OIC as a cause of excessive bleeding. 
In addition, an attempt to identify microthrombi in 
major organs of a canine liver transplant recipient 
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after clinical evidence of intravascular coagulation was 
not successful (22). No clinical sign of ischemic injury 
caused by microthrombi in major vital organs was 
seen in our patients. Fourth, the possibility of trap-
ping of coagulation factors and platelets, especially 
by the poorly preserved donor liver, can be consid-
ered. However, the mean increase in platelet count 
after platelet infusion during the early part of the third 
stage of surgery was not different from that in the 
first stage. Fifth, as postulated by Stremple et aI., 
levels of heparin or a heparin-like substance may be 
increased (23). However, of 13 patients who received 
the TT and reptilase time test, TT was prolonged sig-
nificantly in only two patients, indicating that heparin 
or a heparin-like substance plays a rather minor role 
in coagulopathy. Finally, the effects of other humoral 
and metabolic factors should be emphasized. Meta-
bolic acidosis, decrease in cardiovascular perform-
ance, decreased plasma ionized calcium level, de-
crease in body temperature, and hyperkalemia were 
observed during reperfusion in most patients; and all 
of these could adversely affect the coagulation system. 
The blood coagulability measured by TEG improved 
without significant changes in levels of coagulation 
factors 30 min after reperfusion in a significant num-
ber of patients. That is not sufficient time to expect 
the functional recovery of the donor liver, although 
it coincided with the recovery of the above physiologic 
variables. Thus metabolic and humoral changes that 
occur with the reperfusion of the homograft may in-
terfere with the hemostatic process more than has 
been recognized. 
All coagulation profile and TEG variables started 
to improve 30 min after reperfusion of the liver and, 
with the exception of factor V and factor VIII, all the 
factor levels and ELT returned toward the baseline 
value within 2 hr after reperfusion. This agrees with 
the findings of Groth (6), and it appears that recovery 
of the coagulation system coincides with bile pro-
duction and the metabolism of citrate (Marquez JM, 
unpublished data, 1984). 
In this series of patients, blood replacement ther-
apy was guided by TEG monitoring. TEG, developed 
in the 1950s, has been used mostly for research pur-
poses and is a simple, reliable, and sensitive method. 
A general assessment of blood coagulation status can 
be obtained within 30 min (8,24), and the coagulation 
process is assessed continuously and rapidly in the 
operating room. TEG measures the coagulation pro-
cess in whole blood, rather than testing blood co-
agulability in anticoagulated plasma, as is commonly 
done to obtain the conventional analytic coagulation 
profile. The interpretation of TEG and its relation to 
the conventional coagulation profile has been estab-
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lished by several researchers (25,26). The reaction time 
(R) is closely related to aPTT. The maximum ampli-
tude (MA) is a reflection of platelet function and ac-
tivity of factor XIII. The rate of clot formation (cr) pri-
marily reflects the function of fibrinogen, and it 
increases with improved platelet function. The whole 
blood clot lysis time (F) is reported to be closely related 
to EL T. To express the activity of whole blood clot 
lysis, the ratio A6o:MA was used. 
In general, the correlation between the TEG vari-
ables and coagulation profile measurements in the 
patients studied is similar to results published by oth-
ers, although it was not high in these patients, prob-
ably because of both the large standard deviations in 
the individual data and other physiologic changes. 
Since replacement of blood products was guided by 
the TEG monitoring, as described in Methods, there 
were fewer significant changes in R, R + k, MA, and 
a values during the first stage, although there were 
decreases in coagulation factors and platelets. This 
discrepancy may indicate that blood coagulability was 
maintained in spite of low but higher than critical 
levels of coagulation factors. 
The effectiveness of the TEG-guided replacement 
therapy is shown in a representative TEG pattern (Fig. 
4). Poor preoperative coagulation status was im-
proved by selective transfusion of FFP, platelets, and 
cryoprecipitate; and blood coagulability was normal 
at the end of surgery after transfusion of 46 units of 
RBC, 48 units of FFP, 20 units of platelets, and 12 
units of cryoprecipitate. The clinical significance of 
TEG-guided replacement therapy is demonstrated in 
the volumes patients received during the surgical pro-
cedure. Treatment of patients in the control group, 
who received liver transplants from 1981 to 1982, was 
guided by clinical impression and the results of PT, 
aPTT, and platelet count. Since TEG monitoring be-
gan, the required volume of fluid infusion has de-
creased by 33%. Defects in the coagulation system 
were treated with platelets or cryoprecipitate when 
needed. All but two patients in the TEG-monitored 
group received veno-venous bypass, and the im-
proved surgical technique could have contributed to 
the reduction in blood loss. However, because of the 
magnitude of the intraoperative bleeding, a con-
trolled, randomized study could not be justified. Fur-
thermore, it is not unreasonable to speculate that pa-
tients in the TEG-monitored group had better blood 
coagulability because TEG patterns were normal to-
ward the end of surgery. The total number of blood 
donors to which patients were exposed remained sim-
ilar, even though patients in the TEG-monitored group 
received more platelets and cryoprecipitate; therefore 
exposure to hepatitis or acquired immune deficiency 
Case LW. 
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Figure 4. Thrombelastographic pattern of one patient. Reaction 
time, maximum amplitude, and clot formation rate improved after 
sequential transfusion of FFP, platelets, and cryoprecipitate. Rapid 
whole blood clot lysis was demonstrated during the second stage 
and the early part of the third stage of surgery. Transfusion of 
platelets and cryoprecipitate normalized the TEG pattern at the end 
of the operation. This patient was transfused 46 units of RBC, 48 
units of FFP, 20 units of platelets, and 12 units of cryoprecipitate. 
syndrome was not increased in patients of the TEG-
monitored group. 
In this series of 66 patients, very severe coagulo-
pathy was observed ranging from no clotting at all to 
a rapid whole blood clot lysis (within 0.5 hr), which 
often was associated with blood transfusions in excess 
of 50 L. Normalizing the levels of platelets and co-
agulation factors may not always be possible. How-
ever, maintaining the blood coagulability is critically 
important for these patients who have marginal or no 
liver function. This study showed intraoperative 
changes in coagulation and the clinical effectiveness 
of TEG monitoring and TEG-guided replacement 
therapy. Further investigation is required for a better 
understanding of the clinical use of TEG and antifi-
brinolytic therapy to reduce morbidity and mortality 
in patients undergoing liver transplantation. 
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